156 related articles for article (PubMed ID: 9566718)
1. Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells.
Levenson AS; Svoboda KM; Kwaan HC; Jordan VC
Cancer Lett; 1998 Mar; 125(1-2):215-20. PubMed ID: 9566718
[TBL] [Abstract][Full Text] [Related]
2. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
Levenson AS; Kwaan HC; Svoboda KM; Weiss IM; Sakurai S; Jordan VC
Br J Cancer; 1998 Jul; 78(1):88-95. PubMed ID: 9662256
[TBL] [Abstract][Full Text] [Related]
3. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor.
Levenson AS; Catherino WH; Jordan VC
J Steroid Biochem Mol Biol; 1997 Mar; 60(5-6):261-8. PubMed ID: 9219916
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
[TBL] [Abstract][Full Text] [Related]
5. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor.
Schafer JI; Liu H; Tonetti DA; Jordan VC
Cancer Res; 1999 Sep; 59(17):4308-13. PubMed ID: 10485477
[TBL] [Abstract][Full Text] [Related]
6. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
7. Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells.
Tonetti DA; Rubenstein R; DeLeon M; Zhao H; Pappas SG; Bentrem DJ; Chen B; Constantinou A; Craig Jordan V
J Steroid Biochem Mol Biol; 2003 Oct; 87(1):47-55. PubMed ID: 14630090
[TBL] [Abstract][Full Text] [Related]
8. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER.
Jiang SY; Langan-Fahey SM; Stella AL; McCague R; Jordan VC
Mol Endocrinol; 1992 Dec; 6(12):2167-74. PubMed ID: 1491696
[TBL] [Abstract][Full Text] [Related]
9. The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor.
Levenson AS; Tonetti DA; Jordan VC
Br J Cancer; 1998 Jun; 77(11):1812-9. PubMed ID: 9667651
[TBL] [Abstract][Full Text] [Related]
10. The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells.
Abidi SM; Howard EW; Dmytryk JJ; Pento JT
Clin Exp Metastasis; 1998 Apr; 16(3):235-41. PubMed ID: 9568641
[TBL] [Abstract][Full Text] [Related]
11. Invasive capacity and regulation of urokinase-type plasminogen activator in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells, and a transfectant (S30) stably expressing ER.
Long BJ; Rose DP
Cancer Lett; 1996 Feb; 99(2):209-15. PubMed ID: 8616826
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells.
MacGregor Schafer J; Liu H; Levenson AS; Horiguchi J; Chen Z; Jordan VC
J Steroid Biochem Mol Biol; 2001 Jul; 78(1):41-50. PubMed ID: 11530283
[TBL] [Abstract][Full Text] [Related]
13. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
[TBL] [Abstract][Full Text] [Related]
14. A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens.
Jiang SY; Parker CJ; Jordan VC
Breast Cancer Res Treat; 1993; 26(2):139-47. PubMed ID: 8219251
[TBL] [Abstract][Full Text] [Related]
15. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog.
Catherino WH; Wolf DM; Jordan VC
Mol Endocrinol; 1995 Aug; 9(8):1053-63. PubMed ID: 7476979
[TBL] [Abstract][Full Text] [Related]
16. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
Poulin R; Merand Y; Poirier D; Levesque C; Dufour JM; Labrie F
Breast Cancer Res Treat; 1989 Oct; 14(1):65-76. PubMed ID: 2605344
[TBL] [Abstract][Full Text] [Related]
18. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the "estrogenicity" of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes.
Barkhem T; Andersson-Ross C; Höglund M; Nilsson S
J Steroid Biochem Mol Biol; 1997 May; 62(1):53-64. PubMed ID: 9366498
[TBL] [Abstract][Full Text] [Related]
20. Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12.
Pearce ST; Liu H; Jordan VC
J Biol Chem; 2003 Feb; 278(9):7630-8. PubMed ID: 12496244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
